Polyuria-polydipsia syndrome (thirst and passing large volumes of urine) in adults
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Initial work-up: confirm polyuria and rule out common causes
Urine tests
- 24-hour urine collection to measure urine output (empty the bladder at the start, collect all urine until the same time the next day, final voids included).
- Urine dipstick (glycosuria, proteinuria, leucocytes)
Laboratory tests
- Plasma glucose
- Serum electrolytes (sodium, potassium)
- Serum calcium
- Serum creatinine with eGFR
- Urine osmolality on a spot sample (if polyuria confirmed)if needednon-French guidelineConfirmed polyuria without diabetes mellitus, hypercalcaemia, hypokalaemia or renal failure: a urine osmolality above 700 mOsm/kg excludes central diabetes insipidus [1]. Not reimbursed in France (outside the fee schedule).
- Serum lithium (if on lithium)if needednon-French guidelinePatient treated with lithium: lithium causes nephrogenic diabetes insipidus [1]. See the page "Treatment: lithium".
Also consider
- Raised plasma glucose or glycosuria? See the page "Diabetes: new finding of hyperglycaemia" to confirm and type the diabetes.
- On lithium? Measure serum lithium and see the page "Treatment: lithium".
- High serum sodium? High serum sodium comes under the page "Hypernatraemia".
Do not order
- HbA1c to look for diabetes mellitus: the NABM (French laboratory fee schedule) limits reimbursement to monitoring of glycaemic control; plasma glucose is enough [10].
Confirmed hypotonic polyuria without obvious cause: specialist advice
- Endocrinology opinion: distinguish AVP deficiency (central diabetes insipidus), AVP resistance (nephrogenic) and primary polydipsia by a dynamic test in a specialist setting (copeptin after arginine stimulation or hypertonic saline, or water deprivation test), then hypothalamic-pituitary MRI depending on the result.
- Do not perform a water deprivation test in the community.
Sources (13)
- Tomkins M, Lawless S, Martin-Grace J, Sherlock M, Thompson CJ. Diagnosis and Management of Central Diabetes Insipidus in Adults. J Clin Endocrinol Metab. 2022;107(10):2701-15.
- Flynn K, Hatfield J, Brown K, Vietor N, Hoang T. Central and nephrogenic diabetes insipidus: updates on diagnosis and management. Front Endocrinol (Lausanne). 2024;15:1479764.
- ANSM, Base de données publique des médicaments. Résumé des caractéristiques du produit HOLOXAN 1000 mg (ifosfamide), poudre pour solution injectable, rubrique 4.8 (mise à jour du 21/05/2026), consulté le 12/10/2026.
- Marques P, Gunawardana K, Grossman A. Transient diabetes insipidus in pregnancy. Endocrinol Diabetes Metab Case Rep. 2015;2015:150078 (rapport de cas avec revue de la littérature).
- Working Group for Renaming Diabetes Insipidus ; Arima H, Cheetham T, Christ-Crain M, et al. Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus. Endocr Connect. 2022;11(11):e220378 (publication simultanée dans plusieurs revues).
- American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S27-S49.
- Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Typ-2-Diabetes, Langfassung, Version 3.0, 2023.
- Royal Australian College of General Practitioners, Diabetes Australia. Management of type 2 diabetes: a handbook for general practice. Novembre 2024, mis à jour en août 2025 : chapitre « Defining and diagnosing type 2 diabetes ».
- Baldeweg SE, Ball S, Brooke A, et al. Society for Endocrinology Clinical Guidance: Inpatient management of cranial diabetes insipidus. Endocr Connect. 2018;7(7):G8-G11.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : acte 1577 (HbA1c).
- Winzeler B, Cesana-Nigro N, Refardt J, et al. Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study. Lancet. 2019;394(10198):587-595.
- Refardt J, Atila C, Chifu I, et al. Arginine or Hypertonic Saline-Stimulated Copeptin to Diagnose AVP Deficiency. N Engl J Med. 2023;389(20):1877-1887.
- Royal United Hospitals Bath NHS Foundation Trust, Clinical Biochemistry Department. Investigation of Diabetes Insipidus using Copeptin. Protocole DIAB-ENDO-020, version 4, 4 juin 2024.